

DRUG PRIOR AUTHORIZATION COMMITTEE

March 17, 2011
TENTATIVE AGENDA

10:00 - 10:05	Welcome, Announcements and Introductions	Acting Chairman
10:05 - 10:15	Minutes Review	Discussion/ Approval
10:15- 11:30	Pharmacy Program/ Budget Update PDL Process Discussion	Rhonda Driver/ Andrew Haslag
11:30 - 11:35	DUR Update	Rhonda Driver

Old Business

11:35 - 12:05	a. Implementation Schedule (Criteria for Previously Approved Clinical Edits, Step Therapies and PA's)	
---------------	--	--

New Business

12:05 – 12:20	a. New Drug/Product Reviews Proposed Actions (See website and Attached Summary) <ul style="list-style-type: none">i. Open Accessii. Clinical Edit/Step Therapyiii. PDL Productsiv. Prior Authorization<ul style="list-style-type: none">• Discussion• Public Hearing• Decision	Rhonda Driver/ Mark Roaseau
	b. Short Acting Narcotics <ul style="list-style-type: none">• Discussion• Public Hearing• Decision	

12:20-1:45 *Proposed New Program Actions of Existing Products*

- | | | |
|----|---|--|
| a. | <u>Drug List (PDL)</u> <ul style="list-style-type: none">i. Androgen Hormonal Inhibitors<ul style="list-style-type: none">• Discussion• Public Hearing• Decisionii. Antiemetics-Oral<ul style="list-style-type: none">• Discussion• Public Hearing• Decisioniii. Bezoyl Peroxide/Clindamycin Topical Agents<ul style="list-style-type: none">• Discussion• Public Hearing• Decisioniv. Beta Adrenergic Agents-Long Acting<ul style="list-style-type: none">• Discussion• Public Hearing• Decisionv. Beta Adrenergic Agents-Nebulized<ul style="list-style-type: none">• Discussion• Public Hearing• Decisionvi. Beta Adrenergic Agents-Short Acting<ul style="list-style-type: none">• Discussion• Public Hearing• Decisionvii. COPD Anticholinergics<ul style="list-style-type: none">• Discussion• Public Hearing• Decision | |
|----|---|--|

- viii. **Growth Hormones**
 - Discussion
 - Public Hearing
 - Decision
- ix. **Hematopoietic Agents**
 - Discussion
 - Public Hearing
 - Decision
- x. **Inhaled Corticosteroids**
 - Discussion
 - Public Hearing
 - Decision
- xi. **Insulins**
 - Discussion
 - Public Hearing
 - Decision
- xii. **Long Acting Insulins**
 - Discussion
 - Public Hearing
 - Decision
- xiii. **Rapid Acting Insulins**
 - Discussion
 - Public Hearing
 - Decision
- xiv. **Insulin-Mix**
 - Discussion
 - Public Hearing
 - Decision
- xv. **Low Molecular Weight Heparins**
 - Discussion
 - Public Hearing
 - Decision
- xvi. **Non-Ergot Dopamine Receptor Agonists**
 - Discussion
 - Public Hearing
 - Decision
- xvii. **Ophthalmic NSAIDS**
 - Discussion
 - Public Hearing
 - Decision
- xviii. **Platelet Inhibitor Agents**
 - Discussion
 - Public Hearing
 - Decision
- xix. **Sedative Hypnotics**
 - Discussion
 - Public Hearing
 - Decision
- xx. **Skeletal Muscle Relaxants**
 - Discussion
 - Public Hearing
 - Decision
- xxi. **Stains**
 - Discussion
 - Public Hearing
 - Decision
- xxii. **Triglyceride Lowering Agents**
 - Discussion
 - Public Hearing
 - Decision
- xxiii. **Urinary tract Antispasmodics**
 - Discussion
 - Public Hearing
 - Decision

c. **Preferred Drug List**

- i. Process discussion
- ii. Therapeutic classes-to be *announced at meeting*

1:45

LUNCH

2:00-2:20

Program Utilization Information

Rhonda Driver

2:20-2:30

Other Business

- i. *Top 25" Drugs by Cost*
- ii. *Clinical Edit Summary Report*
- iii. *Call Center Statistics*

*Informal comments will be accepted from members of the audience at various points in the agenda.
Times noted are approximate, Agenda may move more quickly*

Executive Session

2:30-2:35

Minutes Review

Discussion/Approval

2:35-3:00

Case Reviews

Jenna Twehus

NEXT MEETING: June 16, 2011 – 205 Jefferson Street, 10th Floor